ERBB2 and breast cancer: GLUT4 overexpression enhances glycolysis in HER2‐positive breast cancer cells resulting in resistance to HER2‐targeting trastuzumab and lapatinib.[87] In cisplatin‐resistant colon cancer cells, increased YTHDF1 is responsible for cisplatin resistance due to alteration in glutamine metabolism.